Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma

被引：41

作者：

Homburg, Ursula ^{[1
]}

Renz, Harald ^{[2
,3
]}

Timmer, Wolfgang

Hohlfeld, Jens M. ^{[4
]}

Seitz, Friedeborg ^{[5
]}

Lueer, Katrin ^{[4
]}

Mayer, Alexandra ^{[5
]}

Wacker, Anja ^{[6
]}

Schmidt, Oliver ^{[6
]}

Kuhlmann, Jens ^{[1
]}

Turowska, Agnieszka ^{[1
]}

Roller, Julia ^{[7
]}

Kutz, Klaus ^{[8
]}

Schlueter, Gerhard

Krug, Norbert ^{[4
]}

Garn, Holger ^{[2
,3
]}

机构：

[1] Sterna Biol GmbH, Marburg, Germany

[2] Univ Giessen, Univ Marburg, Fac Med, Inst Lab Med & Pathobiochem Mol Diagnost, Marburg, Germany

[3] Marburg Lung Ctr UGMLC, Marburg, Germany

[4] Fraunhofer Inst Toxicol & Expt Med, Dept Clin Airway Res, Hannover, Germany

[5] CRS Clin Res Serv Mannheim GmbH, Mannheim, Germany

[6] Engelhard Arzneimittel GmbH, Niederdorfelden, Germany

[7] Vectura GmbH, Gauting, Germany

[8] AccelPharm, Basel, Switzerland

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 136卷 / 03期

关键词：

GATA-3-SPECIFIC DNAZYME; ACTIVATION; EXPRESSION; TOXICITY; EXPOSURE; HGD40;

D O I：

10.1016/j.jaci.2015.02.018

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：797 / +

页数：4

共 41 条

[31] Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
Borte, M.
Krivan, G.
Derfalvi, B.
Marodi, L.
Harrer, T.
Jolles, S.
Bourgeois, C.
Engl, W.
Leibl, H.
McCoy, B.
Gelmont, D.
Yel, L.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 187 (01): : 146 - 159
[32] miR-146a-3p as a potential novel therapeutic by targeting MBD2 to mediate Th17 differentiation in Th17 predominant neutrophilic severe asthma
Duan, Wentao
Huang, Jin
Wasti, Binaya
Chen, Zhifeng
Yuan, Yu
He, Yi
Li, Danhong
Jia, Jingsi
Liu, Shaokun
Liu, Yi
Ma, Libing
Zeng, Qingping
Zhu, Liming
Li, Jianmin
Zhang, Xiufeng
Xiang, Xudong
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2839 - 2854
[33] miR-146a-3p as a potential novel therapeutic by targeting MBD2 to mediate Th17 differentiation in Th17 predominant neutrophilic severe asthma
Wentao Duan
Jin Huang
Binaya Wasti
Zhifeng Chen
Yu Yuan
Yi He
Danhong Li
Jingsi Jia
Shaokun Liu
Yi Liu
Libing Ma
Qingping Zeng
Liming zhu
Jianmin Li
Xiufeng Zhang
Xudong Xiang
Clinical and Experimental Medicine, 2023, 23 : 2839 - 2854
[34] Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
Eulalia Jimenez
Carol Astbury
Muna Albayaty
Ulrika Wählby-Hamrén
Beatriz Seoane
Cristina Villarroel
Helena Pujol
Maria Jesus Bermejo
Ajay Aggarwal
Ioannis Psallidas
Respiratory Research, 21
[35] Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
Jimenez, Eulalia
Astbury, Carol
Albayaty, Muna
Waehlby-Hamren, Ulrika
Seoane, Beatriz
Villarroel, Cristina
Pujol, Helena
Bermejo, Maria Jesus
Aggarwal, Ajay
Psallidas, Ioannis
RESPIRATORY RESEARCH, 2020, 21 (Suppl 1)
[36] MM-111-A Novel Bispecific Antibody Targeting HER-2/HER-3 Z Heterodimer: Safety and Tolerability in a First-In Human Phase I/II Study in Patients with Refractory HER2-Positive (HER-2+) Cancers
Beeram, M.
Denlinger, C. S.
Tolcher, A. W.
Goldstein, L. J.
Patnaik, A.
Papadopoulos, K.
Murray, J.
McDonagh, C.
Andreas, K.
Niyikiza, C.
Moyo, V. M.
CANCER RESEARCH, 2010, 70
[37] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Bleecker, Eugene R.
FitzGerald, J. Mark
Chanez, Pascal
Papi, Alberto
Weinstein, Steven F.
Barker, Peter
Sproule, Stephanie
Gilmartin, Geoffrey
Aurivillius, Magnus
Werkstrom, Viktoria
Goldman, Mitchell
LANCET, 2016, 388 (10056): : 2115 - 2127
[38] The effect of KRP-204/N-5984 (a novel beta3-adrenergic receptor agonist) on visceral fat surface (VFS) and safety/tolerability parameters in obese patients with type 2 diabetes mellitus (T2DM)
Wing, Jeff R.
Du Toit, Johan J.
Van Der Walt, Jan S.
Johnstone, Hilary L.
DIABETES, 2006, 55 : A398 - A398
[39] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
Cheng, Ying
Lisberg, Aaron
Lemech, Charlotte
Abed, Afaf
Chaudhry, Arvind
Schmidt, Andrew
Lu, Xin
Zhu, Zhongyuan
Gu, Wei
Qiu, Yang
Shi, Rong
Zhang, Bin
CANCER RESEARCH, 2024, 84 (07)
[40] A phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced/metastatic solid tumors
Lisberg, Aaron
Lu, Shun
Starodub, Alexander
Amin, Harshad
Rotow, Julia
Wu, Lin
Spira, Alexander
Hamilton, Erika
Shen, Weidi
Liu, Liming
Zhu, Zhongyuan
Gu, Wei
Qiu, Yang
Shi, Rong
Liu, Shengxue
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →